Serious setback for Genmab in DuoBody collaboration
Genmab has suffered a significant setback for one of the early clinical assets being developed in a collaboration with Janssen after a phase I study has been put on clinical hold.
BY STEFAN SINGH KAILAY
“All three have enormous potential, but what is important for me, is that they validate the platform. We now have five commercial agreements against the background of the platform and more than 75 percent of the internal pipeline is based on the technology, so it is profoundly important for Genmab’s future.”
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
Med din prøveperiode får du:
Få fuld adgang til dig og dine kollegaer
Start et gratis virksomhedsprøveabonnementRelaterede artikler
"It is profoundly important for Genmab’s future"
For abonnenter
Janssen wants more success from Genmab partnership
For abonnenter
